Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Title I—Prescription Drug User Fee Amendments of 2007 | Statement: [Food and Drug Administration Amendments Act of 2007, hasSection, Title I—Prescription Drug User Fee Amendments of 2007]

Target entity: Title I—Prescription Drug User Fee Amendments of 2007
Context triple: [Food and Drug Administration Amendments Act of 2007, hasSection, Title I—Prescription Drug User Fee Amendments of 2007]

• A. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• B. Food and Drug Administration Amendments Act of 2007
  The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
• C. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• D. Food and Drug Administration Safety and Innovation Act of 2012
  The Food and Drug Administration Safety and Innovation Act of 2012 is a U.S. federal law that reauthorized and expanded FDA user fee programs while enhancing the agency’s authority over drug and medical device safety, innovation, and supply chain oversight.
• E. Medicare Prescription Drug, Improvement, and Modernization Act of 2003
  The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is a major U.S. federal law that overhauled Medicare by adding outpatient prescription drug coverage and expanding private plan options for beneficiaries.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: Title I—Prescription Drug User Fee Amendments of 2007
Triple: [Food and Drug Administration Amendments Act of 2007, hasSection, Title I—Prescription Drug User Fee Amendments of 2007]

Title I—Prescription Drug User Fee Amendments of 2007 is the portion of the Food and Drug Administration Amendments Act of 2007 that reauthorizes and modifies the FDA’s prescription drug user fee program to support the review of new drug applications.

Target entity: Title I—Prescription Drug User Fee Amendments of 2007
Target entity description: Title I—Prescription Drug User Fee Amendments of 2007 is the portion of the Food and Drug Administration Amendments Act of 2007 that reauthorizes and modifies the FDA’s prescription drug user fee program to support the review of new drug applications.

• A. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• B. Food and Drug Administration Amendments Act of 2007 chosen
  The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
• C. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• D. Food and Drug Administration Safety and Innovation Act of 2012
  The Food and Drug Administration Safety and Innovation Act of 2012 is a U.S. federal law that reauthorized and expanded FDA user fee programs while enhancing the agency’s authority over drug and medical device safety, innovation, and supply chain oversight.
• E. Medicare Prescription Drug, Improvement, and Modernization Act of 2003
  The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is a major U.S. federal law that overhauled Medicare by adding outpatient prescription drug coverage and expanding private plan options for beneficiaries.
• F. None of above.